- 7/14/2022
- 5/17/2022Safety And Efficacy of BLU-5937 In the Treatment of Refractory Chronic Cough from the Phase 2b SOOTHE Trial. ATS 2022.
En Savoir Plus - 5/17/2022Safety And Efficacy of BLU-5937 In the Treatment of Refractory Chronic Cough from the Phase 2b SOOTHE Trial. ATS 2022.
En Savoir Plus - 5/16/2022Responders Analyses in Objective 24H Cough Frequency in SOOTHE, A Phase 2b Trial of a Selective P2x3 Antagonist in Refractory Chronic Cough. ATS 2022.
En Savoir Plus - 5/16/2022Improvements in Cough Severity and Quality of Life in SOOTHE, A Phase 2b, Dose Finding Trial of BLU-5937 in Refractory Chronic Cough. ATS 2022.
En Savoir Plus - 9/5/2021Improvements in cough severity and cough related quality of life in a phase 2 trial with BLU 5937 in refractory chronic cough. ERS 2021.
En Savoir Plus - 6/12/2021Update on the Development of BLU 5937 for the Treatment of Refractory Chronic Cough. American Cough Conference 2021.
En Savoir Plus - 5/20/2021Design of SOOTHE, a Phase 2b Dose Finding Study with BLU 5937, a Selective P2X3 Antagonist, in Refractory Chronic Cough. Am. J Respir Crit Care Med . ATS 2021.
En Savoir Plus - 5/20/2021Improvements in Cough Frequency over 24 Hours with BLU 5937, a Selective P2X3 Antagonist, in Patient Subgroups Defined by Baseline Awake Cough Frequencies. Am. J Respir Crit Care Med. ATS 2021.
En Savoir Plus - 5/20/2021Baseline Characteristics and Burden of Disease in Populations Defined by Cough Frequency Tiers in RELIEF, a Phase 2 Study on the Efficacy and Safety of BLU 5937 in Refractory Chronic Cough. Am. J Respir Crit Care Med. ATS 2021.
En Savoir Plus - 1/22/2021Results of RELIEF, a Phase 2a Study with BLU-5937 in Refractory Chronic Cough. The Eleventh International Virtual Cough Symposium.
En Savoir Plus - 1/22/2021BLU-5937, A Potent and Selective P2X3 Receptor Antagonist, Presents a Promising New Approach for the Treatment of Chronic Pruritus in Atopic Dermatitis Patients. The Eleventh International Virtual Cough Symposium.
En Savoir Plus - 9/21/2019BLU-5937; A Potent and Selective P2X3 Antogonist, for the Treatment of Chronic Itch: Evidence from Preclinical Studies. 2019 European Society for Dermatological Research Conference.
En Savoir Plus - 6/7/2019BLU-5937: A Highly Selective P2X3 Homotrimeric Receptor Antagonist, Exhibits Excellent Pharmacokinetic and Safety Profile Including Improved Taste Safety Profile in Healthy Subjects. 2019 American Cough Conference.
En Savoir Plus - 5/21/2019BLU-5937 a Highly Selective P2X3 Homotrimeric Receptor Antagonist with Improved Taste Safety Profile in Healthy Subjects. 2019 American Thoracic Society Conference.
En Savoir Plus - 3/20/2019BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. ELSEVIER.
En Savoir Plus - 6/27/2018BLU-5937: A Selective P2X3 Antagonist With Potent Anti-Tussive Effect and No Taste Alteration. International Cough Symposium .
En Savoir Plus
Science
Publications scientifiques